Replies to post #153789 on Biotech Values

[mcbio]

Targeting KRAS in lung cancer with a MEK inhibitor


pharmastrategyblog.com/2012/11/effectively-targeting-kras-in-lung-cancer-with-a-mek-inhibitor.html/

Sally says this is the first time that she has seen really solid evidence of a MEK inhibitor added to standard chemotherapy in 2nd-line NSCLC that significantly improved overall survival in patients with KRAS mutations.

I don't think there is any new news here. I think the big caveat still remains about those Phase 2 KRAS NSCLC OS results not being stat sig. PFS and RR looked good but plenty of questions remain about OS since results weren't stat sig and were "non-proportional" (believe that was the language).

[mcbio]

AZN/(ARRY) - new P2 trial for selumetinib

[H/t to @lomu_j on Twitter for this find of a new P2 trial of selumetinib that AZN is now running in KRAS NSCLC with the apparent objective of exploring if better tolerability can be obtained by lowering the docetaxel dose used in combo w/the same selumetinib dose that was used in the prior P2 trial. If we are to take this at face value and, in spite of the prior trial testing the planned Phase 3 formulation of selumetinib, it would appear that AZN may not be ready to proceed directly into Phase 3 with selumetinib.]

http://clinicaltrials.gov/ct2/show/NCT01750281